CTI BioPharma (CTIC) Shares Slide -6.11%

CTI BioPharma (CTIC) : During the past 4 weeks, traders have been relatively bearish on CTI BioPharma (CTIC), hence the stock is down -9.57% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -6.05% relative to the S&P 500. The 4-week change in the price of the stock is -6.53% and the stock has fallen -6.11% in the past 1 week.

The stock has recorded a 20-day Moving Average of 5.55% and the 50-Day Moving Average is 14.92%. CTI BioPharma Corp. has dropped 33.48% during the last 3-month period . Year-to-Date the stock performance stands at -72.76%.


CTI BioPharma (NASDAQ:CTIC): stock turned positive on Friday. Though the stock opened at $0.344, the bulls momentum made the stock top out at $0.347 level for the day. The stock recorded a low of $0.33 and closed the trading day at $0.335, in the green by 1.70%. The total traded volume for the day was 1,135,666. The stock had closed at $0.3294 in the previous days trading.

CTI BioPharma Corp. (CTI), formerly Cell Therapeutics, Inc., is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers that offer a benefit to patients and healthcare providers. The Company is focused on commercializing PIXUVRI (pixantrone), or PIXUVRI, in the European Union, for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL), and conducting a Phase III clinical trial program of pacritinib for the treatment of adult patients with myelofibrosis to support regulatory submission for approval in the United States and Europe. It is also engaged in evaluating pacritinib in earlier clinical trials as treatment for other blood-related cancers. Its development product candidates include tosedostat and Opaxio.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.